Journal of Cardiac Failure
Volume 14, Issue 5 , Pages 379-387 , June 2008

A Comparison of Patient and Physician-Rated New York Heart Association Class in a Community-Based Heart Failure Clinic

Received 12 September 2007 ,Revised 21 January 2008 ,Accepted 23 January 2008.

References 

  1. Petrie MC, Berry C, Stewart S, McMurray JJ. Failing ageing hearts. Eur Heart J. 2001;22:1978–1990
  2. Hobbs FDR, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23:1867–1876
  3. Heo S, Moser DK, Lennie TA, Zambroski CH, Chung ML. A comparison of health-related quality of life between older adults with heart failure and healthy older adults. Heart Lung. 2007;36:16–24
  4. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–1140
  5. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:10–38
  6. The criteria committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th Edition. Boston, Mass:: Little, Brown & Co; 1994;
  7. Bohm M, Maack C, Wehrlen-Grandjean M, Erdmann E. Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)). Z Kardiol. 2003;92:668–676
  8. Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005;7:1059–1069
  9. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13
  10. Brunner-La Rocca HP, Buser PT, Schindler R, et al. Management of elderly patients with congestive heart failure—design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J. 2006;151:949–955
  11. Muller K, Gamba G, Jaquet F, Hess B. Torsemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV—efficacy and quality of life. Eur J Heart Fail. 2003;5:793–801
  12. Abdulla J, Burchardt H, Abildstrom Z, Kober L, Torp-Pedersen C. The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function. Eur Heart J. 2003;24:2116–2122
  13. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation. 1981;64:1227–1234
  14. Raphael C, Briscoe C, Davies J, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart. 2007;93:476–482
  15. Ekman I, Cleland JG, Andersson B, Swedberg K. Exploring symptoms in chronic heart failure. Eur J Heart Fail. 2005;7:699–703
  16. Bart BA, Shaw LK, McCants CB, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30:1002–1008
  17. van den Broek SA, van Veldhuisen DJ, de Graeff PA, et al. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;70:359–363
  18. Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol. 1996;27:345–352
  19. Bettencourt P, Ferreira A, Dias P, et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail. 2000;6:306–313
  20. Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003;338:107–115
  21. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J. 1998;19:990–1003
  22. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002;105:595–601
  23. Pritchett AM, Jacobsen SJ, Mahoney DW, et al. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol. 2003;41:1036–1043
  24. Otto CM. Textbook of Clinical Echocardiography. (3rd Edition). Elsevier Saunders; 2004;
  25. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687–1713
  26. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777–802
  27. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345
  28. Cleland JG, Shelton R, Nikitin N, et al. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials. Eur J Heart Fail. 2007;9:730–739
  29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174
  30. Subramanian U, Weiner M, Gradus-Pizlo I, et al. Patient perception and provider assessment of severity of heart failure as predictors of hospitalization. Heart Lung. 2005;34:89–98
  31. Street RL, Krupat E, Bell RA, Kravitz RL, Haidet P. Beliefs about control in the physician-patient relationship: effect on communication in medical encounters. J Gen Intern Med. 2003;18:609–616
  32. Cooper-Patrick L, Gallo JJ, Gonzales JJ, et al. Race, gender, and partnership in the patient-physician relationship. JAMA. 1999;282:583–589
  33. Tabenkin H, Goodwin MA, Zyzanski SJ, Stange KC, Medalie JH. Gender differences in time spent during direct observation of doctor-patient encounters. J Womens Health (Larchmt). 2004;13:341–349
  34. Street RL, Gordon HS, Ward MM, Krupat E, Kravitz RL. Patient participation in medical consultations: why some patients are more involved than others. Med Care. 2005;43:960–969
  35. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829–833
  36. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–463
  37. Ekman I, Cleland JG, Swedberg K, et al. Symptoms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail. 2005;11:288–292
  38. Cleland JG, Goode K, Erhardt L, et al. A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovasc Drugs Ther. 2004;18:139–152
  39. Verbrugge LM. Sex differences in complaints and diagnoses. J Behav Med. 1980;3:327–355
  40. Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31:262–270
  41. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245–1255
  42. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71:1106–1107
  43. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736–741
  44. Cleland JG, Swedberg K, Cohen-Solal A, et al. The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Fail. 2000;2:123–132
  45. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet. 2002;360:1631–1639

 Dr Cleland has received grants and speakers' honoraria from Roche Diagnostics related to the clinical use of natriuretic peptides. Dr Goode has received travel and accommodation grants for conference presentation from Roche Diagnostics. Drs Clark and Nabb have no conflicts of interest.

PII: S1071-9164(08)00042-0

doi: 10.1016/j.cardfail.2008.01.014

Journal of Cardiac Failure
Volume 14, Issue 5 , Pages 379-387 , June 2008

Article Tools

* Image Usage & Resolution